Health‐related quality of life Scales: Well‐Being Enquiry for Diabetics; General Well‐being; Diabetes Quality of Life for Youth and Parents' Diabetes Quality of Life
1 finding from 1 review
Hypoglycaemic episodes a) Non‐serious hypoglycaemia
It is very uncertain whether insulin analogues changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with biphasic insulin (very low certainty).
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).
1 finding from 1 review
All‐cause mortality
It is very uncertain whether insulin analogues changes all‐cause mortality compared with biphasic insulin (very low certainty).
1 finding from 1 review
Treatment satisfaction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (%)
1 finding from 1 review
Intervention not reported
Potency/bioactivity parameters of human insulin · healthy physicians
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).
1 finding from 1 review
Intervention not reported
Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention may leads to higher cardiovascular mortality a. Intervention vs placebo [30 weeks to… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal myocardial infarction Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal… (low certainty).
1 finding from 1 review
RR 1.08 [0.81, 1.45]
1 study · 2 participants
Low
Intervention not reported
Cancer Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cancer Intervention vs insulin [4.75 years to 10.0 years] (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cardiovascular mortality a. Intervention vs metformin [a. 24 weeks… (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of type 2 diabetes mellitus · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetic complications · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found